News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
News GSK strikes again, adding COPD candidate in $745m deal In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.
News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News GSK forges $12bn alliance with China's Hengrui GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.
News Roche's COPD candidate fails a phase 3 readout Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.
News GSK claims first approval for Nucala in COPD GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.
News Kyverna rises on stiff person syndrome data Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
